

Fabrizio Schifano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4396406/publications.pdf>

Version: 2024-02-01

113
papers

4,199
citations

101496

36
h-index

133188

59
g-index

118
all docs

118
docs citations

118
times ranked

3568
citing authors

#	ARTICLE	IF	CITATIONS
1	Mephedrone (4-methylmethcathinone; "meow meow"): chemical, pharmacological and clinical issues. <i>Psychopharmacology</i> , 2011, 214, 593-602.	1.5	274
2	Novel psychoactive substances of interest for psychiatry. <i>World Psychiatry</i> , 2015, 14, 15-26.	4.8	257
3	Misuse and Abuse of Pregabalin and Gabapentin: Cause for Concern?. <i>CNS Drugs</i> , 2014, 28, 491-496.	2.7	197
4	When "Chems" Meet Sex: A Rising Phenomenon Called "ChemSex". <i>Current Neuropharmacology</i> , 2017, 15, 762-770.	1.4	148
5	A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's "Suspected Adverse Drug Reactions" Database. <i>CNS Drugs</i> , 2016, 30, 647-654.	2.7	130
6	e-Psychonauts: Conducting research in online drug forum communities. <i>Journal of Mental Health</i> , 2012, 21, 386-394.	1.0	123
7	Cannabidiol (CBD) use in psychiatric disorders: A systematic review. <i>NeuroToxicology</i> , 2019, 74, 282-298.	1.4	107
8	An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 270-277.	1.0	105
9	COVID-19: The Hidden Impact on Mental Health and Drug Addiction. <i>Frontiers in Psychiatry</i> , 2020, 11, 767.	1.3	101
10	Suspected and Confirmed Fatalities Associated With Mephedrone (4-Methylmethcathinone, "Meow") Tj ETQq0 0,0 rgBT /Overlock 10 0,7 96	0.7	96
11	Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): A literature review with a focus on UK fatalities related to non-medical use. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 53, 52-78.	2.9	80
12	25C-NBOME: Preliminary Data on Pharmacology, Psychoactive Effects, and Toxicity of a New Potent and Dangerous Hallucinogenic Drug. <i>BioMed Research International</i> , 2014, 2014, 1-6.	0.9	75
13	The "Endless Trip" among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review. <i>Frontiers in Psychiatry</i> , 2017, 8, 240.	1.3	75
14	Substance Use in the Club Scene of Rome: A Pilot Study. <i>BioMed Research International</i> , 2014, 2014, 1-5.	0.9	71
15	Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135. <i>Neuropharmacology</i> , 2016, 105, 630-638.	2.0	67
16	Mind Navigators of Chemicals' Experimenters? A Web-Based Description of E-Psychonauts. <i>Cyberpsychology, Behavior, and Social Networking</i> , 2015, 18, 296-300.	2.1	66
17	The Use and Impact of Cognitive Enhancers among University Students: A Systematic Review. <i>Brain Sciences</i> , 2021, 11, 355.	1.1	66
18	Psychoactive drug or mystical incense? Overview of the online available information on Spice products. <i>International Journal of Culture and Mental Health</i> , 2009, 2, 137-144.	0.6	62

#	ARTICLE	IF	CITATIONS
19	Personality dimensions and psychopathological profiles of Ecstasy users. <i>Human Psychopharmacology</i> , 2001, 16, 635-639.	0.7	60
20	Novel psychoactive substance consumption is more represented in bipolar disorder than in psychotic disorders: A multicenter observational study. <i>Human Psychopharmacology</i> , 2017, 32, e2578.	0.7	59
21	Profiling online recreational/prescription drugs' customers and overview of drug vending virtual marketplaces. <i>Human Psychopharmacology</i> , 2015, 30, 302-318.	0.7	58
22	Assessing the 2004-2018 Fentanyl Misusing Issues Reported to an International Range of Adverse Reporting Systems. <i>Frontiers in Pharmacology</i> , 2019, 10, 46.	1.6	58
23	An international survey on the awareness, use, preference, and health perception of novel psychoactive substances (NPS). <i>Human Psychopharmacology</i> , 2017, 32, e2581.	0.7	57
24	Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review. <i>Brain Sciences</i> , 2018, 8, 73.	1.1	56
25	Substance-related exogenous psychosis: a postmodern syndrome. <i>CNS Spectrums</i> , 2021, 26, 84-91.	0.7	54
26	“New/Designer Benzodiazepines”™: An Analysis of the Literature and Psychonauts™ Trip Reports. <i>Current Neuropharmacology</i> , 2020, 18, 809-837.	1.4	51
27	Sexual Enhancement Products for Sale Online: Raising Awareness of the Psychoactive Effects of Yohimbine, Maca, Horny Goat Weed, and <i>Ginkgo biloba</i>. <i>BioMed Research International</i> , 2014, 2014, 1-13.	0.9	50
28	Monitoring novel psychoactive substances allegedly offered online for sale in Persian and Arabic languages. <i>International Journal of Drug Policy</i> , 2014, 25, 724-726.	1.6	50
29	The clinical challenges of synthetic cathinones. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 410-419.	1.1	50
30	Anabolic androgenic steroid abuse in the United Kingdom: An update. <i>British Journal of Pharmacology</i> , 2020, 177, 2180-2198.	2.7	49
31	An insight into the deep web; why it matters for addiction psychiatry?. <i>Human Psychopharmacology</i> , 2017, 32, e2573.	0.7	48
32	Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 943-954.	1.3	47
33	A systematic review of the nature of dispensing errors in hospital pharmacies. <i>Integrated Pharmacy Research & Practice</i> , 2016, 5, 1.	0.9	46
34	Intended and unintended use of cathinone mixtures. <i>Human Psychopharmacology</i> , 2017, 32, e2598.	0.7	46
35	Focus on Over-the-Counter Drugs' Misuse: A Systematic Review on Antihistamines, Cough Medicines, and Decongestants. <i>Frontiers in Psychiatry</i> , 2021, 12, 657397.	1.3	40
36	Cocaine/crack cocaine consumption, treatment demand, seizures, related offences, prices, average purity levels and deaths in the UK (1990-2004). <i>Journal of Psychopharmacology</i> , 2008, 22, 71-79.	2.0	39

#	ARTICLE	IF	CITATIONS
37	Synthetic Cannabinoid use in a Case Series of Patients with Psychosis Presenting to Acute Psychiatric Settings: Clinical Presentation and Management Issues. <i>Brain Sciences</i> , 2018, 8, 133.	1.1	37
38	What about "Pharming"? Issues Regarding the Misuse of Prescription and Over-the-Counter Drugs. <i>Brain Sciences</i> , 2020, 10, 736.	1.1	36
39	Herbal Highs: Review on Psychoactive Effects and Neuropharmacology. <i>Current Neuropharmacology</i> , 2017, 15, 750-761.	1.4	36
40	Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms. <i>Human Psychopharmacology</i> , 2015, 30, 249-254.	0.7	32
41	"Bundle of fun" or "bunch of problems"? Case series of khat-related deaths in the UK. <i>Drugs: Education, Prevention and Policy</i> , 2011, 18, 408-425.	0.8	31
42	Is there such a thing as a 'loper' dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports. <i>PLoS ONE</i> , 2018, 13, e0204443.	1.1	30
43	NPS: Medical Consequences Associated with Their Intake. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 32, 351-380.	0.8	29
44	New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review. <i>Experimental Neurology</i> , 2021, 339, 113638.	2.0	29
45	How deaths can help clinicians and policymakers understand the risks of novel psychoactive substances. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 482-498.	1.1	28
46	Deaths in the Lesbian, Gay, Bisexual and Transgender United Kingdom Communities Associated with GHB and Precursors. <i>Current Drug Metabolism</i> , 2018, 19, 1086-1099.	0.7	28
47	Is There a Potential of Misuse for Venlafaxine and Bupropion?. <i>Frontiers in Pharmacology</i> , 2018, 9, 239.	1.6	27
48	"Agonists as Misusing Drugs? Assessment of both Clenbuterol and Salbutamol-related European Medicines Agency Pharmacovigilance Database Reports. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 182-187.	1.2	26
49	Cannabis; Epidemiological, Neurobiological and Psychopathological Issues: An Update. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017, 16, 598-609.	0.8	25
50	Pregabalin: A range of misuse-related unanswered questions. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 659-660.	1.9	24
51	The Bridge Between Classical and "Synthetic"/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective. <i>Frontiers in Psychiatry</i> , 2019, 10, 851.	1.3	24
52	The Psychonauts' World of Cognitive Enhancers. <i>Frontiers in Psychiatry</i> , 2020, 11, 546796.	1.3	24
53	Novel Opioids: Systematic Web Crawling Within the e-Psychonauts' Scenario. <i>Frontiers in Neuroscience</i> , 2020, 14, 149.	1.4	24
54	Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach. <i>Frontiers in Psychiatry</i> , 2020, 11, 632405.	1.3	24

#	ARTICLE	IF	CITATIONS
55	Recent Changes in Drug Abuse Scenarios: The New/Novel Psychoactive Substances (NPS) Phenomenon. <i>Brain Sciences</i> , 2018, 8, 221.	1.1	22
56	Substance-related psychopathology and aggressiveness in a nightlife holiday resort: Results from a pilot study in a psychiatric inpatient unit in Ibiza. <i>Human Psychopharmacology</i> , 2017, 32, e2586.	0.7	21
57	Evolutionary Considerations on the Emerging Subculture of the E-psychonauts and the Novel Psychoactive Substances: A Comeback to the Shamanism?. <i>Current Neuropharmacology</i> , 2017, 15, 731-737.	1.4	21
58	Beyond the "purple drank"™: Study of promethazine abuse according to the European Medicines Agency adverse drug reaction reports. <i>Journal of Psychopharmacology</i> , 2021, 35, 681-692.	2.0	21
59	Availability of Illegal Drugs During the COVID-19 Pandemic in Western Germany. <i>Frontiers in Psychiatry</i> , 2021, 12, 648273.	1.3	21
60	Role of patient-reported outcomes and other efficacy endpoints in the drug approval process in Europe (2008-2012). <i>Journal of Epidemiology and Global Health</i> , 2015, 5, 385.	1.1	20
61	Exploration of the Use of New Psychoactive Substances by Individuals in Treatment for Substance Misuse in the UK. <i>Brain Sciences</i> , 2018, 8, 58.	1.1	20
62	Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database. <i>Brain Sciences</i> , 2020, 10, 105.	1.1	20
63	Patterns of Management of Patients With Dual Disorder (Psychosis) in Italy: A Survey of Psychiatrists and Other Physicians Focusing on Clinical Practice. <i>Frontiers in Psychiatry</i> , 2018, 9, 575.	1.3	19
64	Piloting the UK's First Home-Office-Licensed Pharmacist-Led Drug Checking Service at a Community Substance Misuse Service. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2020, 10, 121.	1.0	18
65	Benefits and Harms of "Smart Drugs" (Nootropics) in Healthy Individuals. <i>Drugs</i> , 2022, 82, 633-647.	4.9	17
66	4,4'-Dimethylaminorex (4,4'-DMAR; "Serotoni") misuse: A Web-based study. <i>Human Psychopharmacology</i> , 2017, 32, e2575.	0.7	16
67	The use of new psychoactive substances (NPS) in young people and their role in mental health care: a systematic review. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 1253-1264.	1.4	16
68	Impact of the UK Psychoactive Substances Act on awareness, use, experiences and knowledge of potential associated health risks of novel psychoactive substances. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 505-516.	1.1	16
69	New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature. <i>Medicina (Lithuania)</i> , 2021, 57, 580.	0.8	16
70	The e-Psychonauts' "Spiced" World; Assessment of the Synthetic Cannabinoids' Information Available Online. <i>Current Neuropharmacology</i> , 2020, 18, 966-1051.	1.4	16
71	The consequences of drug misuse on post-marketing surveillance. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 867-871.	1.3	15
72	Club Drugs: Psychotropic Effects and Psychopathological Characteristics of a Sample of Inpatients. <i>Frontiers in Psychiatry</i> , 2020, 11, 879.	1.3	15

#	ARTICLE	IF	CITATIONS
73	Venlafaxine as the "baby ecstasy"? Literature overview and analysis of web-based misusers' experiences. <i>Human Psychopharmacology</i> , 2015, 30, 255-261.	0.7	14
74	The e-psychonaut drugs' psychopharmacology. <i>Current Opinion in Pharmacology</i> , 2021, 57, 165-174.	1.7	14
75	Is there a potential of misuse for <i>Magnolia officinalis</i> compounds/metabolites?. <i>Human Psychopharmacology</i> , 2017, 32, e2595.	0.7	13
76	Quetiapine Abuse Fourteen Years Later: Where Are We Now? A Systematic Review. <i>Substance Use and Misuse</i> , 2020, 55, 304-313.	0.7	13
77	Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs. <i>Psychotherapy and Psychosomatics</i> , 2020, 89, 274-282.	4.0	13
78	Case Report: Treatment of Kratom Use Disorder With a Classical Tricyclic Antidepressant. <i>Frontiers in Psychiatry</i> , 2021, 12, 640218.	1.3	13
79	Psychonauts' psychedelics: A systematic, multilingual, web-crawling exercise. <i>European Neuropsychopharmacology</i> , 2021, 49, 69-92.	0.3	13
80	The potential utility of some legal highs in CNS disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 64, 267-274.	2.5	12
81	A matter of life and death: substance-caused and substance-related fatalities in Ibiza in 2015. <i>Human Psychopharmacology</i> , 2017, 32, e2592.	0.7	11
82	COVID-19 Pandemic Impact on Substance Misuse: A Social Media Listening, Mixed Method Analysis. <i>Brain Sciences</i> , 2021, 11, 907.	1.1	11
83	Is there a Teratogenicity Risk Associated with Cannabis and Synthetic Cannabimimetics' ("Spice") Intake? <i>CNS and Neurological Disorders - Drug Targets</i> , 2017, 16, 585-591.	0.8	11
84	Is urbanization a risk factor for substance misuse?. <i>Current Opinion in Psychiatry</i> , 2008, 21, 391-397.	3.1	10
85	Psychedelic Fauna for Psychonaut Hunters: A Mini-Review. <i>Frontiers in Psychiatry</i> , 2018, 9, 153.	1.3	10
86	Misuse of Anticholinergic Medications: A Systematic Review. <i>Biomedicines</i> , 2022, 10, 355.	1.4	10
87	Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS). <i>Pharmaceuticals</i> , 2022, 15, 675.	1.7	10
88	Exploring the Baseline Knowledge and Experience of Healthcare Professionals in the United Kingdom on Novel Psychoactive Substances. <i>Brain Sciences</i> , 2020, 10, 142.	1.1	9
89	What About Drug Checking? Systematic Review and Netnographic Analysis of Social Media. <i>Current Neuropharmacology</i> , 2020, 18, 906-917.	1.4	9
90	A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases. <i>Pharmaceuticals</i> , 2022, 15, 565.	1.7	9

#	ARTICLE	IF	CITATIONS
91	Analyzing the Open/Deep Web to Better Understand the New/Novel Psychoactive Substances (NPS) Scenarios: Suggestions from CASSANDRA and NPS.Finder Research Projects. <i>Brain Sciences</i> , 2020, 10, 146.	1.1	8
92	Club Drugs and Psychiatric Sequelae: An Issue of Vulnerability and Previous Psychiatric History. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 6944.	1.2	8
93	Medications mostly associated with priapism events: assessment of the 2015â€“2020 Food and Drug Administration (FDA) pharmacovigilance database entries. <i>International Journal of Impotence Research</i> , 2024, 36, 50-54.	1.0	8
94	Impact of an 18â€“Month, NHSâ€“Based, Treatment Exposure for Heroin Dependence: Results from the London Area Treat 2000 Study. <i>American Journal on Addictions</i> , 2012, 21, 268-273.	1.3	7
95	New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues. <i>Current Addiction Reports</i> , 2019, 6, 140-152.	1.6	7
96	Is medicinal ketamine associated with urinary dysfunction issues? Assessment of both the European Medicines Agency (<sc>EMA</sc>) and the <sc>UK</sc> Yellow Card Scheme pharmacovigilance databaseâ€“related reports. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021, 13, 230-237.	0.6	7
97	Opioid painkiller dependence in a sample of elderly medical inpatients. <i>Psychogeriatrics</i> , 2021, 21, 265-271.	0.6	7
98	Assessing prevalence, knowledge and use of cognitive enhancers among university students in the United Arab Emirates: A quantitative study. <i>PLoS ONE</i> , 2022, 17, e0262704.	1.1	7
99	Is the Urine Cannabinoid Level Measured via a Commercial Point-of-Care Semiquantitative Immunoassay a Cannabis Withdrawal Syndrome Severity Predictor?. <i>Frontiers in Psychiatry</i> , 2020, 11, 598150.	1.3	6
100	The Psychonautsâ€™™ Benzodiazepines; Quantitative Structure-Activity Relationship (QSAR) Analysis and Docking Prediction of Their Biological Activity. <i>Pharmaceuticals</i> , 2021, 14, 720.	1.7	6
101	Prescription Drug Misuse in â€œClubbersâ€“and Disco Goers in Ibiza. <i>Frontiers in Psychiatry</i> , 2020, 11, 592594.	1.3	5
102	Are finasteride-related penile curvature/Peyronieâ€™™s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases. <i>International Journal of Impotence Research</i> , 2023, 35, 465-471.	1.0	5
103	Novel psychoactive substances: first international conference. <i>Human Psychopharmacology</i> , 2013, 28, 287-288.	0.7	3
104	Editorial: Prescribing Psychotropics: Misuse, Abuse, Dependence, Withdrawal and Addiction. <i>Frontiers in Psychiatry</i> , 2021, 12, 688434.	1.3	3
105	Worsening of the Toxic Effects of (Â±)Cis-4,4â€“DMAR Following Its Co-Administration with (Â±)Trans-4,4â€“DMAR: Neuro-Behavioural, Physiological, Immunohistochemical and Metabolic Studies in Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8771.	1.8	3
106	Designer Benzodiazepinesâ€™™ Activity on Opioid Receptors: A Docking Study. <i>Current Pharmaceutical Design</i> , 2022, 28, 2639-2652.	0.9	3
107	Knowledge and Use of Over-the-counter Drugs in Italy: An Exploratory Survey-based Study in the General Population. <i>Current Neuropharmacology</i> , 2023, 21, 133-141.	1.4	3
108	Recreational Drugs' Scenario and Compulsory Treatment in the United Kingdom. <i>International Journal of Mental Health</i> , 2008, 37, 22-56.	0.5	1

#	ARTICLE	IF	CITATIONS
109	Use of benzylglycinamide by a HIV-seropositive polysubstance user: The changing pattern of novel psychoactive substance use among youths. <i>Addictive Behaviors</i> , 2016, 60, 53-57.	1.7	1
110	Joint versus separate inpatient rehabilitation treatment for patients with alcohol use disorder or drug use disorder: an observational study. <i>Substance Abuse and Rehabilitation</i> , 2018, Volume 9, 23-29.	1.6	1
111	The New Future Pharmacology Journal: A Cutting-Edge Opportunity for Rapidly Sharing and Widely Disseminating the Most Advanced Research Ideas and Findings. <i>Future Pharmacology</i> , 2021, 1, 1-2.	0.6	0
112	Knowledge and Use of Novel Psychoactive Substances in Italy: a Survey-Based Study in the General Population. <i>International Journal of Mental Health and Addiction</i> , 0, , 1.	4.4	0
113	New Access Routes to Undertreated Populations; How Do Problem Substance Users Recruited from an Unemployment Office Differ from Detoxification Treatment Inpatients?. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 13014.	1.2	0